Skip to main content
UniHealth

Doctor search

Edwin A Alvarez, MD

Gynecological Oncology · San Francisco

NPI 1710197330

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
2
Since medical school
26 years
University of California, San Diego School of Medicine, 2000

Offices

2 locations · University of California San Francisco · UCSF Medical Group Business Services

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Alvarez’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence A78109 · Current

Licensed to practise in California · since 2002 · expires 2027-07-31 · University of California, San Diego School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Obstetrics and Gynecology - Gynecologic Oncology
  • American Board of Obstetrics and Gynecology - Obstetrics and Gynecology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$80,669

Medicare paid this office $80,669 for 164 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)64$21,516$126
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes20$7,295$104
Return visit (30+ min)59$6,651$84
New patient visit (60+ min)40$6,439$161
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's99$3,131$15
See all 7 services
Every Original Medicare service billed
Long return visit (40+ min)64$21,516$126
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes20$7,295$104
Return visit (30+ min)59$6,651$84
New patient visit (60+ min)40$6,439$161
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's99$3,131$15
Short return visit (20+ min)43$2,546$50
Short return visit15$469$29

Procedures Medicare counted

Procedure volume Medicare published
Colonoscopy1-10None
Removal of the uterus13More than 87% of doctors who do this

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less––15–––

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

164 Original Medicare patients in 2024. Average age 71 · Women 100% · Also on Medicaid 40% · Health risk score 2.06. Above the middle of the specialty; the typical gynecological oncology clinician is at 1.53.

Conditions among them: High blood pressure 71% · Cancer 51% · Diabetes 33% · Chronic kidney disease 30% · Depression 29% · Atrial fibrillation 17% · Coronary heart disease 13% · Heart failure 13% · COPD 13% · Dementia 7% · Stroke 7%.

The office billed $520,308, Medicare allowed $102,889 and paid $80,669; for 702 services of 40 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024164702712.06$520,308$80,669
2023140396722.07$399,455$61,855
2022138411711.86$388,812$61,053
2021150427691.72$453,756$71,986
202095309701.84$265,890$38,233
201994282691.97$259,864$37,543
201880191722.37$194,275$28,327
201761151692.12$129,463$19,791
2016167398702.12$241,432$51,127
2015198521701.89$337,796$73,055
2014162422701.78$232,832$54,397
201386196691.61$145,824$33,673

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Original Medicare services billed in 2023
Long return visit (40+ min)45$13,846$121
New patient visit (60+ min)39$5,979$153
Return visit (30+ min)42$4,254$87
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes11$3,902$105
Short return visit (20+ min)47$2,944$53
Short return visit21$691$30

2022: 6 services

Original Medicare services billed in 2022
Long return visit (40+ min)46$12,299$127
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$7,865$90
New patient visit (60+ min)53$7,854$148
Return visit (30+ min)37$3,517$78
Short return visit (20+ min)34$2,083$56
Hospital discharge day management, 30 minutes or less14$1,355$65

2021: 8 services

Original Medicare services billed in 2021
Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less15$12,359$824
New patient visit (60+ min)57$9,933$174
Long return visit (40+ min)40$9,805$132
Return visit (30+ min)57$8,974$87
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes24$4,622$86
Short return visit (20+ min)23$1,561$60
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes11$981$89
Hospital discharge day management, 30 minutes or less13$918$66

2020: 4 services

Original Medicare services billed in 2020
Return visit (30+ min)42$6,064$67
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$4,314$94
Short return visit (20+ min)33$2,897$46
New patient visit (30+ min)14$966$69

2019: 5 services

Original Medicare services billed in 2019
Return visit (30+ min)42$5,951$68
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$4,112$93
New patient visit (60+ min)14$1,966$140
New patient visit (30+ min)19$1,291$68
Short return visit (20+ min)18$1,012$46

2018: 3 services

Original Medicare services billed in 2018
Return visit (30+ min)35$4,406$66
New patient visit (60+ min)19$2,831$149
Short return visit (20+ min)23$1,359$45

2017: 4 services

Original Medicare services billed in 2017
New patient visit (60+ min)16$2,267$142
Short return visit (20+ min)23$1,912$46
Return visit (30+ min)18$1,779$66
New patient visit (45+ min)11$1,268$115

2016: 9 services

Original Medicare services billed in 2016
Return visit (30+ min)50$4,879$60
Short return visit (20+ min)65$2,915$35
Long return visit (40+ min)24$2,559$83
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes13$2,395$83
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes16$2,005$57
New patient visit (60+ min)13$1,552$119
New patient visit (45+ min)13$1,143$88
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes11$1,080$77
Short return visit23$388$15

2015: 9 services

Original Medicare services billed in 2015
Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less12$8,088$674
New patient visit (60+ min)39$5,216$134
Short return visit (20+ min)66$4,636$38
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes20$4,571$85
Return visit (30+ min)52$4,457$59
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes23$3,412$59
New patient visit (45+ min)16$1,440$90
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes12$1,067$82
Short return visit33$745$21

2014: 6 services

Original Medicare services billed in 2014
Return visit (30+ min)69$8,319$61
New patient visit (60+ min)41$5,334$130
Short return visit (20+ min)61$3,925$41
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$1,512$58
New patient visit (45+ min)13$1,362$105
Short return visit16$284$18

2013: 4 services

Original Medicare services billed in 2013
New patient visit (60+ min)27$3,562$132
Return visit (30+ min)29$2,148$58
Short return visit (20+ min)29$1,601$39
Long return visit (40+ min)15$1,408$83

Medicaid work

$40,201 in 2024

Medicaid paid $40,201 for 283 billed services this clinician did in 2024, up to 20 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Clinic visit/encounter, all-inclusive63$21,515
Long return visit (40+ min)131$17,075
Short return visit (20+ min)18$749
Return visit (30+ min)14$629
Telehealth transmission, per minute, professional services bill separately27$232
Service30$0
Medicaid work by year
2024283620$40,201
2023210616$31,662
2022191419$12,388
2021153320$11,705
202097220$5,322
2019201220$20,265
2018118218$25,086
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Clinic visit/encounter, all-inclusive85$25,650
Long return visit (40+ min)32$4,435
Short return visit (20+ min)13$878
Telehealth originating site facility fee13$500
Telehealth transmission, per minute, professional services bill separately29$198
Service38$0

2022

Largest Medicaid services in 2022
Long return visit (40+ min)77$8,901
Telehealth originating site facility fee50$1,850
Return visit (30+ min)17$1,227
Telehealth transmission, per minute, professional services bill separately47$410

2021

Largest Medicaid services in 2021
Return visit (30+ min)112$8,652
Long return visit (40+ min)13$1,864
Telehealth originating site facility fee28$1,189

2020

Largest Medicaid services in 2020
Return visit (30+ min)82$5,271
Telehealth transmission, per minute, professional services bill separately15$51

2019

Largest Medicaid services in 2019
Return visit (30+ min)170$10,610
Clinic visit/encounter, all-inclusive31$9,654

2018

Largest Medicaid services in 2018
Clinic visit/encounter, all-inclusive69$21,688
Return visit (30+ min)49$3,399

Drugs they prescribed that Part D paid

$187,441

Pharmacies billed $187,441 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

95 generic and 27 brand-name prescriptions · $187,441 in drug cost · 15 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Ondansetron12$61$3

Year by year

Part D prescribing by year
202412239None22%$187,441
202310635NoneNone$20,508
2022124390% (0)13%$163,234
202116338None7%$79,998
2020127360% (0)21%$247,804
201913633NoneNone$119,320
201811227NoneNone$117,979
20176726NoneNone$1,629
2016215488% (17)12%$29,555
20152644816% (43)None$30,226
20142214712% (26)None$24,296
20131222414% (17)None$14,302

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 2 drugs

Part D drugs prescribed in 2023
Letrozole13$348$27
Ondansetron12$112$9

2022: 2 drugs

Part D drugs prescribed in 2022
Ondansetron20$336$17
Dexamethasone11$271$25

2021: 4 drugs

Part D drugs prescribed in 2021
Ondansetron20$361$18
Prochlorperazine Maleate24$263$11
Letrozole16$223$14
Gabapentin12$115$10

2020: 3 drugs

Part D drugs prescribed in 2020
Lynparza12$177,391$14,783
Megestrol Acetate14$838$60
Ondansetron21$617$29

2019: 2 drugs

Part D drugs prescribed in 2019
Ondansetron12$114$9
Prochlorperazine Maleate14$101$7

2017: 1 drug

Part D drugs prescribed in 2017
Gabapentin11$110$10

2016: 6 drugs

Part D drugs prescribed in 2016
Anastrozole28$332$12
Duloxetine15$315$21
Ondansetron20$180$9
Letrozole12$163$14
Prochlorperazine Maleate21$120$6
Lorazepam13$61$5

2015: 7 drugs

Part D drugs prescribed in 2015
Hydrocodone-Acetaminophen25$621$25
Ondansetron31$398$13
Amitriptyline17$176$10
Letrozole15$143$10
Anastrozole16$131$8
Prochlorperazine Maleate16$77$5
Lorazepam16$60$4

2014: 6 drugs

Part D drugs prescribed in 2014
Megestrol Acetate11$283$26
Ondansetron20$255$13
Hydrocodone-Acetaminophen14$231$16
Letrozole15$209$14
Prochlorperazine Maleate18$99$5
Dexamethasone19$55$3

2013: 4 drugs

Part D drugs prescribed in 2013
Hydrocodone-Acetaminophen13$175$13
Lorazepam16$70$4
Prochlorperazine Maleate14$70$5
Dexamethasone15$48$3

Money from drug and device companies

$241 in 2024

Industry payments by year
202456None$241
202333$1,900$1,945
202211$1,170$1,170
202133$6,630$6,651
202013None$59
201936$1,620$1,805

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Intuitive SurgicalDa Vinci Surgical System$92
1 payment
  • Meals for Da Vinci Surgical System · 2024-05-14 · $92
GlaxoSmithKlineZejula$65
1 payment
  • Education for Zejula · 2024-09-09 · $65
Ethicon USHarmonic$56
1 payment
  • Meals for Harmonic · 2024-04-16 · $56
ViiV HealthcareDovato$15
1 payment
  • Meals for Dovato · 2024-09-05 · $15
PfizerTivdak$14
2 payments
  • Meals for Tivdak · 2024-05-08 · $12
  • Meals for Tivdak · 2024-05-07 · $2
See all 6 published payments
Every published payment
GlaxoSmithKlineEducation · 2024-09-09Zejula$65
ViiV HealthcareMeals · 2024-09-05Dovato$15
Intuitive SurgicalMeals · 2024-05-14Da Vinci Surgical System$92
PfizerMeals · 2024-05-08Tivdak$12
PfizerMeals · 2024-05-07Tivdak$2
Ethicon USMeals · 2024-04-16Harmonic$56
See earlier years (2023, 2022, 2021, 2020, 2019)

2023: $1,945

Payments by company in 2023
EMD Serono Research & Development InstituteNone$1,900
1 payment
  • Consulting · 2023-12-18 · $1,900
ViiV HealthcareCabenuva$30
1 payment
  • Meals for Cabenuva · 2023-12-19 · $30
Medline Industries LpNone$15
1 payment
  • Meals · 2023-09-19 · $15

2022: $1,170

Payments by company in 2022
EisaiNone$1,170
1 payment
  • Consulting · 2022-09-15 · $1,170

2021: $6,651

Payments by company in 2021
EisaiLenvima$4,680
1 payment
  • Consulting for Lenvima · 2021-10-21 · $4,680
GlaxoSmithKlineZejula$1,950
1 payment
  • Consulting for Zejula · 2021-08-24 · $1,950
Boston ScientificResonate$21
1 payment
  • Meals for Resonate · 2021-03-18 · $21

2020: $59

Payments by company in 2020
Boston ScientificLux-Dx$59
3 payments
  • Meals for Lux-Dx · 2020-12-04 · $21
  • Meals for Emblem · 2020-09-22 · $18
  • Meals for Resonate · 2020-06-17 · $20

2019: $1,805

Payments by company in 2019
EisaiLenvima$1,620
1 payment
  • Consulting for Lenvima · 2019-08-24 · $1,620
Merck Sharp & DohmeNone$115
1 payment
  • Meals · 2019-06-02 · $115
Intuitive SurgicalDa Vinci Surgical System$71
4 payments
  • Meals for Da Vinci Surgical System · 2019-12-24 · $21
  • Meals for Da Vinci Surgical System · 2019-12-24 · $15
  • Meals for Da Vinci Surgical System · 2019-12-24 · $21
  • Meals for Da Vinci Surgical System · 2019-12-24 · $15

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2020Their institution$380,339
Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2019Their institution$351,920
Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2021Their institution$190,266
Genmab U.S., Inc. · A Phase 3 Randomized, Open-Label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator'S Choice (Ic) in Patients With Platinum Resistant Ovarian Cancer · 2025Their institution$73,605
Genentech, Inc. · Multicenter Multi Cohort Open Label Ph2 Study of Biomarker Driven Therapies for Recurrent R Oc Pat · 2024Their institution$62,535
Sumitomo Pharma America, Inc. · Multicenter, Open-Label, Phase I Study of Dsp-7888 Dosing Emulsion in Patients With Advanced Malignancies · 2024Their institution$52,337
Genentech, Inc. · Multicenter Multi Cohort Open Label Ph2 Study of Biomarker Driven Therapies for Recurrent R Oc Pat · 2023Their institution$50,000
Merck Sharp & Dohme LLC · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2022Their institution$46,825
TRILLIUM THERAPEUTICS USA, LLC · A Phase 12 Study of Tti 622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinumresistant Ovarian Cancer · 2024Their institution$36,522
Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician'S Choice in Subjects With Advanced Endometrial Cancer · 2019Their institution$32,492
Genentech, Inc. · Multicenter Multi Cohort Open Label Ph2 Study of Biomarker Driven Therapies for Recurrent R Oc Pat · 2025Their institution$31,598
Genmab A/S · A Phase 2 Exploratory, Multicenter, Open-Label Trial To Determine the Safety and Preliminary Clinical Activity of Gen1046 in Combination With Anticancer Agents in Subjects With Advanced Endometrial Cancer · 2024Their institution$25,622
Merck Sharp & Dohme LLC · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2024Their institution$4,862
Merck Sharp & Dohme LLC · A Multicenter, Open-Label, Randomized, Phase 3 Trial To Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician S Choice in Subjects With Advanced Endometrial Cancer · 2023Their institution$1,712

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
91.9 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1710197330
Licence
CA A78109California A78109: Current · expires 2027-07-31
Trained
University of California, San Diego School of Medicine, 2000 · 26 years ago
Group
University of California San Francisco · UCSF Medical Group Business Services
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 00A781090
Taxonomy
Federal specialty code 207VX0201X (207VX0201X)
Mailing address
4860 Y St, Suite 2500, Sacramento, CA, 95817
NPI first listed
2007-05-23
NPI last updated
2012-12-07

This is when the NPI record was last certified, not a medical board exam.